COCP · Cocrystal Pharma Inc
United States · RS rating 41 · As of 2026-10-14
| Price | 1.04 USD |
|---|---|
| 1-day change | -3.7% |
| RS rating (overall / 1M / 3M / 12M) | 41 / 26 / 85 / 42 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 22 / 24 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -35.3% |
| Sales growth Q/Q | -53.3% |
| Distance from 52-week high | +33.8% |
| Market cap (USD) | $19.4M |